887 results on '"Young, Guy"'
Search Results
52. The past and future of haemophilia: diagnosis, treatments, and its complications
53. The bleeding newborn: A review of presentation, diagnosis, and management
54. Changes in the amino acid sequence of the recombinant human factor VIIa analog, vatreptacog alfa, are associated with clinical immunogenicity
55. Exploratory evaluation of pharmacodynamics, pharmacokinetics and safety of rivaroxaban in children and adolescents: an EINSTEIN-Jr phase I study
56. Rivaroxaban versus standard anticoagulation for acute venous thromboembolism in childhood. Design of the EINSTEIN-Jr phase III study
57. Clinical presentation and therapeutic management of venous thrombosis in young children: a retrospective analysis
58. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab
59. Current practices in pediatric hospital‐acquired thromboembolism: Survey of the Children's Hospital Acquired Thrombosis (CHAT) Consortium
60. Risk of venous thromboembolism in pediatric hospitalized patients undergoing noncardiac surgery: A report from the Children's Hospital‐Acquired Thrombosis consortium
61. Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial
62. FondaKIDS II: Long-term follow-up data of children receiving fondaparinux for treatment of venous thromboembolic events
63. The safety and efficacy of N8-GP (turoctocog alfa pegol) in previously untreated pediatric patients with hemophilia A
64. Pediatric Anticoagulation: Time for a New Paradigm?
65. Safety and efficacy of recombinant activated coagulation factor VII in congenital hemophilia with inhibitors in the home treatment setting: A review of clinical studies and registries
66. Incidence of thrombosis in children with tunneled central venous access devices versus peripherally inserted central catheters (PICCs)
67. Eptacog beta efficacy and safety in the treatment and control of bleeding in paediatric subjects (<12 years) with haemophilia A or B with inhibitors
68. Direct oral anticoagulants for use in paediatrics
69. A novel approach for detecting hypercoagulability utilizing thromboelastography
70. Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives
71. PRO-PACT: Retrospective observational study on the prophylactic use of recombinant factor VIIa in hemophilia patients with inhibitors
72. Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab.
73. Symptomatic pulmonary embolus after catheter removal in children with catheter related thrombosis: A report from the CHAT Consortium
74. Direct Oral Anticoagulants: Overcoming the Challenges of Managing Venous Thromboembolism in Children
75. Can we do something about ICH in hemophilia?
76. Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia
77. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response
78. PREDICT: A Multicenter, Prospective, Open-Label, Clinical Study Using a New Risk Score Approach to Assess the Most Appropriate Prophylaxis Regimen to Reach Favorable Outcomes in Hemophilia A, When Switching from Standard-Half-Life Products to Damoctocog Alfa Pegol
79. Factor VIII Level Comparison in Patients with Severe Hemophilia a on Emicizumab with Inhibitors with One Stage, Bovine and Human Chromogenic Assays and the Factor VIII Equivalency of Emicizumab Using In Vivo Global Hemostasis Assays
80. Efficacy and Safety of Fitusiran Prophylaxis, an siRNA Therapeutic, in a Multicenter Phase 3 Study (ATLAS-INH) in People with Hemophilia A or B, with Inhibitors (PwHI)
81. Eptacog Beta Efficacy in Children and Adolescents with Hemophilia A or B and Inhibitors: Subset Analysis Suggests Improved Caregiver Capacity to Assess Bleeding Episode Resolution with Subject Age
82. Real-World Data of the Hemostatic Efficacy of Recombinant Human Factor VIIa Eptacog Beta for Acute Bleeding Events in Patients with Hemophilia a and B with Inhibitors
83. Cover Image
84. New anticoagulants in children: A review of recent studies and a look to the future
85. The safety of activated eptacog beta in the management of bleeding episodes and perioperative haemostasis in adult and paediatric haemophilia patients with inhibitors
86. Emerging drugs for hemophilia A: insights into phase II and III clinical trials
87. Post‐hoc analysis on the long‐term response to fixed‐dose prophylaxis with N8‐GP in patients with haemophilia A
88. A New Risk Assessment Model for Hospital-Acquired Venous Thromboembolism in Critically Ill Children: A Report From the Children’s Hospital-Acquired Thrombosis Consortium
89. Corrigendum to ‘Evaluation of Venous Thromboembolism Risk Factors Reveals Subtype Heterogenicity in Children with Central Venous Catheters: A Multi-Center Study from the CHAT Consortium’ [Journal of Thrombosis and Haemostasis 21/9 (2023) 2441 - 2450]
90. A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A
91. Pharmacokinetics and Pharmacodynamics of Anticoagulants in Paediatric Patients
92. Development and clinical evaluation of a microarray for hepatitis C virus genotyping
93. Management of children with hemophilia A: How emicizumab has changed the landscape
94. Determining the approximate factor VIII level of patients with severe haemophilia A on emicizumab using in vivo global haemostasis assays
95. Emicizumab prophylaxis in infants with severe haemophilia A without inhibitors: Illustrative real‐world cases to support shared decision‐making
96. Neutralizing antidrug antibody to emicizumab in patients with severe hemophilia A: Case report of a first noninhibitor patient and review of the literature
97. Evaluation of Algorithms for the Treatment of Problem Bleeding Episodes in Patients With Hemophilia Having Inhibitors
98. Predictive Modeling Identifies Total Bleeds at 12-Weeks Postswitch to N8-GP Prophylaxis as a Predictor of Treatment Response.
99. Hemophilia A: Strategies for Improving Long-Term Holistic Management, Adherence, and Quality of Life.
100. Global Laboratory Assays in Hemophilia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.